Next Article in Journal
Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study
Next Article in Special Issue
Endogenous Retroviruses in Nervous System Disorders
Previous Article in Journal
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
Previous Article in Special Issue
Disruption of Cholinergic Circuits as an Area for Targeted Drug Treatment of Alzheimer’s Disease: In Vivo Assessment of Short-Term Plasticity in Rat Brain
Communication

Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study

1
Clinic of Psychiatric Rehabilitation, Department of Psychiatry and Psychotherapy, Faculty of Medical Sciences, Medical University of Silesia in Katowice, Ziołowa 45/47, 40-635 Katowice, Poland
2
Department of Histology, Faculty of Medical Sciences, Medical University of Silesia in Katowice, Medyków 18, 40-752 Katowice, Poland
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(10), 326; https://0-doi-org.brum.beds.ac.uk/10.3390/ph13100326
Received: 22 September 2020 / Revised: 17 October 2020 / Accepted: 20 October 2020 / Published: 21 October 2020
(This article belongs to the Special Issue New Drugs and Biologics For Treatment of Central Nervous Dysfunction)
Bipolar disorder is a chronic and remitting mental illness. Antidepressants are not effective in treating acute bipolar depression, and antipsychotic drugs used in the treatment of bipolar depression cause frequent side effects. This situation justifies the search for new drugs as well as the repurposing of drugs used in other indications. In an open and naturalistic serious case study, 4 patients diagnosed with bipolar I disorder, chronically treated with a mood stabilizer, in whom at least two antidepressants were ineffective in the depressive phase, were treated with amantadine. The woman received 100 mg/day and 3 men received the target dose of 200 mg/day. All patients treated with amantadine improved their depressive symptoms after 1 week of treatment. None of them experienced side effects or manic switch. To reduce the risk of a manic switch, the treatment with amantadine was discontinued 2 weeks after the improvement of depressive symptoms, and no recurrence of depressive symptoms was observed. Amantadine may be a further therapeutic option for the treatment of acute bipolar depression. The drug in this indication may act quickly and be well tolerated. Confirmation of the antidepressant efficacy of amantadine in this indication requires replication of the results and conducting clinical trials. View Full-Text
Keywords: amantadine; bipolar depression; bipolar disorder; off-label treatment amantadine; bipolar depression; bipolar disorder; off-label treatment
Show Figures

Graphical abstract

MDPI and ACS Style

Krzystanek, M.; Pałasz, A. Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study. Pharmaceuticals 2020, 13, 326. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13100326

AMA Style

Krzystanek M, Pałasz A. Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study. Pharmaceuticals. 2020; 13(10):326. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13100326

Chicago/Turabian Style

Krzystanek, Marek, and Artur Pałasz. 2020. "Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study" Pharmaceuticals 13, no. 10: 326. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13100326

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop